Renal parenchymal damage at 6 to 12 months: all included children with acute pyelonephritis DMSA scans · children with acute pyelonephritis
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: all included children… compared with IV followed by oral (11 days) therapy (moderate certainty).
1 finding from 1 review
Renal parenchymal damage at 6 to 12 months: children with renal parenchymal damage on initial DMSA · children with acute pyelonephritis
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: children with renal… compared with IV followed by oral (11 days) therapy (moderate certainty).
1 finding from 1 review
Persistent bacteriuria · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in persistent bacteriuria after treatment compared with long duration (7 to 14 days) IV therapy (low certainty).
1 finding from 1 review
Recurrent UTI within 6 months · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in recurrent UTI within 6 months compared with long duration (7 to 14 days) IV therapy (moderate certainty).
1 finding from 1 review
Persistent renal damage at 3 to 6 months: all included children with acute pyelonephritis · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: all included children with… compared with long duration (7 to 14 days) IV therapy (moderate certainty).
1 finding from 1 review
Persistent renal damage at 3 to 6 months: children with initial renal parenchymal damage on initial DMSA scan · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: children with initial… compared with long duration (7 to 14 days) IV therapy (moderate certainty).
1 finding from 1 review
Persistent bacteriuria after 1 to 3 days of treatment · children with acute pyelonephritis
Different dosing regimens of aminoglycosides (daily showed no clear difference in persistent bacteriuria after 1 to 3 days of treatment compared with 8 hourly) (low certainty).
1 finding from 1 review
Hearing impairment following treatment · children with acute pyelonephritis
Different dosing regimens of aminoglycosides (daily showed no clear difference in hearing impairment following treatment compared with 8 hourly) (low certainty).
1 finding from 1 review
Intervention not reported
Number of people who had not improved or had not been cured ( · children and adults with acute pneumonia
The intervention showed no clear difference in number of people who had not improved or had not been cured ( (low certainty).
1 finding from 1 review
Intervention not reported
Cough score Scale from: 0 (absent) to 3 (very severe) ( · children and adults with acute pneumonia
1 finding from 1 review
Intervention not reported
Adverse events ( · children and adults with acute pneumonia
1 finding from 1 review
Intervention not reported
Complications (e.g. medication change) · children and adults with acute pneumonia
1 finding from 1 review
Tuberculosis · kidney transplant recipients
Isoniazid probably leads to lower tuberculosis compared with no treatment (moderate certainty).
1 finding from 1 review
INH hepatotoxicity Jaundice, elevated bilirubin, elevated liver enzymes · kidney transplant recipients
Isoniazid probably leads to higher INH hepatotoxicity Jaundice, elevated bilirubin, elevated liver… compared with no treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality · kidney transplant recipients
Isoniazid showed no clear difference in all‐cause mortality compared with no treatment (low certainty).
1 finding from 1 review
Maternal and neonatal mortality · women with management of intra‐amniotic infection
1 finding from 1 review
Maternal bacteremia · women with management of intra‐amniotic infection
It is very uncertain whether intrapartum changes maternal bacteremia compared with postpartum treatment (very low certainty).
1 finding from 1 review
Early neonatal sepsis · women with management of intra‐amniotic infection
It is very uncertain whether intrapartum changes early neonatal sepsis compared with postpartum treatment (very low certainty).
1 finding from 1 review
Neonatal pneumonia or sepsis · women with management of intra‐amniotic infection
It is very uncertain whether intrapartum changes neonatal pneumonia or sepsis compared with postpartum treatment (very low certainty).
1 finding from 1 review
Maternal postpartum hospital stay (days) · women with management of intra‐amniotic infection
1 finding from 1 review